11C-Choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT

  • Francesco Ceci
  • Paolo Castellucci
  • Tiziano Graziani
  • Riccardo Schiavina
  • Eugenio Brunocilla
  • Renzo Mazzarotto
  • Maria Ntreta
  • Filippo Lodi
  • Giuseppe Martorana
  • Stefano Fanti
Original Article

Abstract

Purpose

The aim of this retrospective study was to evaluate the usefulness and the detection rate of 11C-choline PET/CT in a population of patients with prostate cancer (PC), exclusively treated with external beam radiotherapy (EBRT) as primary treatment, who showed biochemical relapse.

Materials and methods

We enrolled 140 patients showing a serum PSA level >2 ng/mL (mean 8.6 ng/mL, median 5 ng/mL, range 2 – 60 ng/mL). All patients had been treated with EBRT to the prostate gland and prostatic fossa with doses ranging from 70 to 76 Gy in low-risk patients (T1/T2 and/or serum PSA <10 ng/mL) and escalating to >76 Gy (range 76 – 81 Gy) in high-risk patients (T3/T4 and/or serum PSA >10 ng/mL). Of the 140 patients, 53 were receiving androgen deprivation therapy at the time of the scan. All positive 11C-choline PET/CT findings were validated by transrectal ultrasound-guided biopsy or at least 12 months of follow-up with contrast-enhanced CT, MR, bone scintigraphy or a repeated 11C-choline PET/CT scan. The relationships between the detection rate of 11C-choline PET/CT and the factors PSA level, PSA kinetics, Gleason score, age, time to relapse and SUVmax in patients with positive findings were analysed.

Results

11C-Choline PET/CT detected the site of relapse in 123 of the 140 patients with a detection rate of 87.8 % (46 patients showed local relapse, 31 showed local and distant relapse, and 46 showed only distant relapse). In patients with relapse the mean serum PSA level was 9.08 ng/mL (median 5.1 ng/mL, range 2 – 60 ng/mL), the mean PSA doubling time was 5.6 months (median 3.5 months, range 0.4 – 48 months), and the mean PSA velocity was 15 ng/mL/year (median 8.8 ng/mL/year, range 0.4 – 87 ng/mL/year). Of the 123 patients with relapse, 77 (62.6 %) showed distant relapse with/without local relapse, and of these 77, 31 (40.2 %) showed oligometastatic disease (one or two distant lesions: lymph node lesions only in 16, bone lesions only in 14, and lymph node lesions and bone lesions in 1). In univariate and multivariate analyses PSA kinetics was the only variable affecting 11C-choline PET/CT detection rate. A significant correlation between PSA kinetics and site of recurrence (local relapse only vs. distant metastasis) was also observed.

Conclusion

The detection rate of 11C-choline PET/CT in patients with PC showing biochemical recurrence after EBRT as primary treatment is relatively high (87.8 %). 11C-Choline PET/CT was able to detect extraprostatic disease in the 62.6 % of patients. Considering this high detection rate, 11C-choline PET/CT could have clinical usefulness in the management of these PC patients, but this should be confirmed in future studies.

Keywords

11C-Choline PET/CT (Choline PET) External beam radiotherapy (EBRT) Prostate cancer Biochemical relapse PSA kinetics 

Notes

Acknowledgments

We would like to thank Marcelo Mamede, MD PhD, for his contribution to the final review of the statistical analysis of data and Joshua James Morigi, MD, for his contribution to the language editing.

Conflicts of interest

None.

References

  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.PubMedCrossRefGoogle Scholar
  2. 2.
    Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason MD, Matveev V, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 2011;59:61–71.PubMedCrossRefGoogle Scholar
  3. 3.
    Babaian RJ, Donnelly B, Bahn D, Baust JG, Dineen M, Ellis D, et al. Best practice statement on cryosurgery for the treatment of localized prostate cancer. J Urol. 2008;180:1993–2004.PubMedCrossRefGoogle Scholar
  4. 4.
    Warmuth M, Johansson T, Mad P. Systematic review of the efficacy and safety of high-intensity focussed ultrasound for the primary and salvage treatment of prostate cancer. Eur Urol. 2010;58:803–15.PubMedCrossRefGoogle Scholar
  5. 5.
    Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2011;59:572–83.PubMedCrossRefGoogle Scholar
  6. 6.
    Freedland SJ, Presti Jr JC, Amling CL, Kane CJ, Aronson WJ, Dorey F, et al. Time trends in biochemical recurrence after radical prostatectomy: results of the SEARCH database. Urology. 2003;61:736–41.PubMedCrossRefGoogle Scholar
  7. 7.
    Kane CJ, Amling CL, Johnstone PAS, Pak N, Lance RS, Thrasher JB, et al. Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology. 2003;61:607–11.PubMedCrossRefGoogle Scholar
  8. 8.
    Choueiri TK, Dreicer R, Paciorek A, Carroll PR, Konety B. A model that predicts the probability of positive imaging in prostate cancer cases with biochemical failure after initial definitive local therapy. J Urol. 2008;179(3):906–10.PubMedCrossRefGoogle Scholar
  9. 9.
    Fuccio C, Rubello D, Castellucci P, Marzola MC, Fanti S. Choline PET/CT for prostate cancer: main clinical applications. Eur J Radiol. 2011;80(2):e50–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Castellucci P, Fuccio C, Nanni C, Santi I, Rizzello A, Lodi F, et al. Influence of trigger PSA and PSA kinetics on 11C-choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy. J Nucl Med. 2009;50:1394–400.PubMedCrossRefGoogle Scholar
  11. 11.
    Picchio M, Messa C, Landoni C, Gianolli L, Sironi S, Brioschi M, et al. Value of 11C-choline-positron emission tomography for re-staging prostate cancer: a comparison with 18F-fluorodeoxyglucose-positron emission tomography. J Urol. 2003;169:1337–40.PubMedCrossRefGoogle Scholar
  12. 12.
    Krause BJ, Souvatzoglou M, Tuncel M, Herrmann K, Buck AK, Praus C, et al. The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging. 2008;35(1):18–23.PubMedCrossRefGoogle Scholar
  13. 13.
    Castellucci P, Fuccio C, Rubello D, Schiavina R, Santi I, Nanni C, et al. Is there a role for 11C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml? Eur J Nucl Med Mol Imaging. 2011;38(1):55–63.PubMedCrossRefGoogle Scholar
  14. 14.
    Mamede M, Ceci F, Castellucci P, Schiavina R, Fuccio C, Nanni C, et al. The role of 11C-choline PET imaging in the early detection of recurrence in surgically treated prostate cancer with very low PSA level <0.5 ng/mL. Clin Nucl Med. 2013;38(9):e342–5.PubMedCrossRefGoogle Scholar
  15. 15.
    Pascali C, Bogni A, Iwata R. 11C-methylation on 18C SepPak cartridge: a convenient way to produce [N-methyl-11C]choline. J Labelled Compds Radiopharm. 2000;49:195–203.CrossRefGoogle Scholar
  16. 16.
    Khan MA, Carter HB, Epstein JI, Miller MC, Landis P, Walsh PW, et al. Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer? J Urol. 2003;170:2274–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Khuntia D, Reddy CA, Mahadevan A, Klein EA, Kupelian PA. Recurrence-free survival rates after external-beam radiotherapy for patients with clinical T1–T3 prostate carcinoma in the prostate-specific antigen era: what should we expect? Cancer. 2004;100:1283–92.PubMedCrossRefGoogle Scholar
  18. 18.
    Bolla M, Van Tienhoven G, Warde P, Dubois JB, Mirimanoff RO, Storme G, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol. 2010;11:1066–73.PubMedCrossRefGoogle Scholar
  19. 19.
    Mohler J, Bahnson RR, Boston B, Busby JE, D’Amico A, Eastham JA, et al. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw. 2010;8(2):162–200.PubMedGoogle Scholar
  20. 20.
    Rigatti P, Suardi N, Briganti A, Da Pozzo LF, Tutolo M, Villa L, et al. Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography. Eur Urol. 2011;60(5):935–43.PubMedCrossRefGoogle Scholar
  21. 21.
    Tilki D, Reich O, Graser A, Hacker M, Silchinger J, Becker AJ, et al. 18F-Fluoroethylcholine PET/CT identifies lymph node metastasis in patients with prostate-specific antigen failure after radical prostatectomy but underestimates its extent. Eur Urol. 2013;63(5):792–6.PubMedCrossRefGoogle Scholar
  22. 22.
    Passoni NM, Suardi N, Abdollah F, Picchio M, Giovacchini G, Messa C, et al. Utility of [11C]choline PET/CT in guiding lesion-targeted salvage therapies in patients with prostate cancer recurrence localized to a single lymph node at imaging: results from a pathologically validated series. Urol Oncol. 2013. doi: 10.1016/j.urolonc.2013.03.006
  23. 23.
    Souvatzoglou M, Krause BJ, Pürschel A, Thamm R, Schuster T, Buck AK, et al. Influence of (11)C-choline PET/CT on the treatment planning for salvage radiation therapy in patients with biochemical recurrence of prostate cancer. Radiother Oncol. 2011;99(2):193–200. doi: 10.1016/j.radonc.2011.05.005.PubMedCrossRefGoogle Scholar
  24. 24.
    Würschmidt F, Petersen C, Wahl A, Dahle J, Kretschmer M. [18F]fluoroethylcholine-PET/CT imaging for radiation treatment planning of recurrent and primary prostate cancer with dose escalation to PET/CT-positive lymph nodes. Radiat Oncol. 2011;6:44.PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Berkovic P, De Meerleer G, Delrue L, Lambert B, Fonteyne V, Lumen N, et al. Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy. Clin Genitourin Cancer. 2013;11(1):27–32.PubMedCrossRefGoogle Scholar
  26. 26.
    Chondrogiannis S, Marzola MC, Ferretti A, Maffione AM, Rampin L, Grassetto G, et al. Role of 18F-choline PET/CT in suspicion of relapse following definitive radiotherapy for prostate cancer. Eur J Nucl Med Mol Imaging. 2013;40(9):1356–64.PubMedCrossRefGoogle Scholar
  27. 27.
    Giovacchini G, Picchio M, Scattoni V, Garcia Parra R, Briganti A, Gianolli L, et al. Doubling time for prediction of [(11)C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2010;37(6):1106–16.PubMedCrossRefGoogle Scholar
  28. 28.
    de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ. 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol. 2003;44(1):32–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Giovacchini G, Picchio M, Coradeschi E, Bettinardi V, Gianolli L, Scattoni V, et al. Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2010;37(2):301–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Martino P, Scattoni V, Galosi AB, Consonni P, Trombetta C, Palazzo S, et al. Role of imaging and biopsy to assess local recurrence after definitve treatment for prostate carcinoma (surgery, radiotherapy, cryotherapy, HIFU). World J Urol. 2011;29(5):595–605. doi: 10.1007/s00345-011-0687-y.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Francesco Ceci
    • 1
  • Paolo Castellucci
    • 1
    • 4
  • Tiziano Graziani
    • 1
  • Riccardo Schiavina
    • 2
  • Eugenio Brunocilla
    • 2
  • Renzo Mazzarotto
    • 3
  • Maria Ntreta
    • 3
  • Filippo Lodi
    • 1
  • Giuseppe Martorana
    • 2
  • Stefano Fanti
    • 1
  1. 1.Service of Nuclear Medicine, Policlinico S. Orsola MalpighiUniversity of BolognaBolognaItaly
  2. 2.Department of Urology, Policlinico S. Orsola MalpighiUniversity of BolognaBolognaItaly
  3. 3.Service of Radiotherapy, Policlinico S. Orsola MalpighiUniversity of BolognaBolognaItaly
  4. 4.UO di Medicina Nucleare, PAD. 30Azienda Ospedaliero-Unversitaria di Bologna Policlinico Sant’Orsola-MalpighiBolognaItaly

Personalised recommendations